HONG KONG, Jan. 15, 2026 /PRNewswire/ — AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 15 that its research and development of the iterative process high-efficiency diploid rabies vaccine has successfully completed the Phase III clinical site work. This marks the official entry of the vaccine into a new phase, laying a […]